Skip to main content
DXCM
NASDAQ Industrial Applications And Services

Dexcom Appoints Google's Rick Osterloh to Board, Bolstering Tech & Product Expertise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$74.38
Mkt Cap
$28.626B
52W Low
$54.11
52W High
$90.66
52W Position info
37% above low
Off High info
18% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

DXCM sits 37% above its 52-week low of $54.11.

Summary

Dexcom has appointed Rick Osterloh, Google's Senior VP of Platforms & Devices, to its Board of Directors, bringing significant technology and product leadership experience.


Key Events · Executive and Board Changes · DXCM

  • New Director Appointed

    Dexcom's Board of Directors increased its size to twelve and appointed Albert F. ("Rick") Osterloh, IV as a new independent director, effective February 26, 2026.

  • High-Profile Tech Executive Joins

    Mr. Osterloh currently serves as Senior Vice President, Platforms & Devices at Google, overseeing Android, Google Play, Chrome, and Google's Devices and Services Portfolio (Pixel, Nest, Fitbit). He brings over 20 years of leadership in consumer hardware and platform strategy.

  • Strategic Committee Assignments

    Mr. Osterloh was appointed to serve as a member of the Compensation Committee and the Technology Committee of the Board, effective immediately.

  • Director Compensation Details

    Upon appointment, Mr. Osterloh received an initial equity grant of restricted stock units (RSUs) with a fair value of $500,000, vesting over three years, and will be eligible for an annual pro-rata RSU grant of $101,027.


Analysis · DXCM · Industrial Applications And Services

The appointment of Rick Osterloh, a high-profile technology executive from Google, to Dexcom's Board of Directors is a strategically positive move. Mr. Osterloh's extensive experience in consumer hardware, platform strategy, and integrating advanced technologies like AI at Google aligns directly with Dexcom's mission in glucose biosensing. This addition strengthens the board's expertise in innovation oversight and long-term product development, which is particularly relevant given the company's recent challenges related to product quality and regulatory scrutiny. His presence could signal a renewed focus on enhancing product capabilities and strategic technological advancements.

At the time of this filing, DXCM was trading at $74.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.6B. The 52-week trading range was $54.11 to $90.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DXCM - Latest Insights

DXCM
Jun 12, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $75.54
Real-time Price: $75.76 info
Change: +$0.2152 (+0.28%) info
Market Cap: $29.234B info
DXCM
Jun 06, 2026, 2:45 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $71.50
Real-time Price: $75.76 info
Change: +$4.26 (+6%) info
Market Cap: $29.234B info
DXCM
May 28, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $72.19
Real-time Price: $75.76 info
Change: +$3.57 (+5%) info
Market Cap: $29.234B info
DXCM
May 26, 2026, 9:46 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $71.15
Real-time Price: $75.76 info
Change: +$4.61 (+6%) info
Market Cap: $29.234B info
DXCM
May 15, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $59.66
Real-time Price: $75.76 info
Change: +$16.10 (+27%) info
Market Cap: $29.234B info